Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations |
| |
| Authors: | Michael Soyka Andreas G Franke |
| |
| Institution: | Psychiatric Hospital, University of Munich, München 80336, Germany. ed.nehcneum-inu.dem@akyos.leahcim;University of Applied Labour Studies, Mannheim 68163, Germany |
| |
| Abstract: | Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed. |
| |
| Keywords: | Opioids Opioid dependence Maintenance treatment Methadone Buprenorphine Depot Implant |
|
